Medicenna Therapeutics Corp. Opens the Market

TORONTO, May 25, 2017 /CNW/ - Fahar Merchant, PhD, Co-Founder, Chairman, President and CEO, Medicenna Therapeutics Corp. (MDNA), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Medicenna is a clinical stage immuno-oncology company that is developing therapeutics for the treatment of central nervous system cancers. Medicenna Therapeutics Corp. commenced trading on the TSX Venture Exchange on March 3, 2017.

SOURCE TMX Group Limited

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890